TipRanks
Advertisement
Advertisement

SGIOF Stock Latest News

Shionogi’s Phase 3 COVID-19 Antiviral Trial Puts SGIOF Back in the Spotlight
Company AnnouncementsShionogi’s Phase 3 COVID-19 Antiviral Trial Puts SGIOF Back in the Spotlight
2d ago
SGIOF
Shionogi Wins Pediatric Approval for VTAMA Atopic Dermatitis Cream in Japan
PremiumCompany Announcements
Shionogi Wins Pediatric Approval for VTAMA Atopic Dermatitis Cream in Japan
3d ago
Shionogi Wins Japan Approval for JN.1 COVID Booster, Advances Vaccine Platform
PremiumCompany Announcements
Shionogi Wins Japan Approval for JN.1 COVID Booster, Advances Vaccine Platform
3d ago
Shionogi Targets Rare Disease Growth With New Pompe Study on S-606001
PremiumCompany Announcements
Shionogi Targets Rare Disease Growth With New Pompe Study on S-606001
24d ago
SGIOF
Shionogi Extends Pompe Program: What S-606001’s New Phase 2 Study Means for SGIOF Investors
PremiumCompany Announcements
Shionogi Extends Pompe Program: What S-606001’s New Phase 2 Study Means for SGIOF Investors
1M ago
SGIOF
Shionogi Advances Phase 3 Secutrelvir Trial, Eyeing New COVID-19 Market Upside
PremiumCompany AnnouncementsShionogi Advances Phase 3 Secutrelvir Trial, Eyeing New COVID-19 Market Upside
1M ago
SGIOF
Shionogi’s Q1 Earnings Surge on Acquisitions, HIV Royalties and Overseas Growth
Premium
Company Announcements
Shionogi’s Q1 Earnings Surge on Acquisitions, HIV Royalties and Overseas Growth
2M ago
Shionogi’s Q1 FY2026 Profit Surges on Strong Revenue Growth, Full-Year Guidance Intact
Premium
Company Announcements
Shionogi’s Q1 FY2026 Profit Surges on Strong Revenue Growth, Full-Year Guidance Intact
2M ago
SGIOF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
SGIOF Earnings this Week: How Will it Perform?
2M ago
Shionogi’s Redasemtide Stroke Trial Completion: What Investors Should Watch Next
PremiumCompany Announcements
Shionogi’s Redasemtide Stroke Trial Completion: What Investors Should Watch Next
2M ago
SGIOF
Shionogi Targets Pediatric Opioid Side Effects With New Naldemedine Study
PremiumCompany Announcements
Shionogi Targets Pediatric Opioid Side Effects With New Naldemedine Study
2M ago
SGIOF
Shionogi Completes Treasury Share Disposal for Restricted Stock Compensation Plan
PremiumCompany Announcements
Shionogi Completes Treasury Share Disposal for Restricted Stock Compensation Plan
2M ago
Shionogi to Dispose Treasury Shares for Expanded Restricted Stock Compensation Plan
PremiumCompany AnnouncementsShionogi to Dispose Treasury Shares for Expanded Restricted Stock Compensation Plan
3M ago
Shionogi Adopts New Policies to Align Management With Capital Costs and Stock Prices
Premium
Company Announcements
Shionogi Adopts New Policies to Align Management With Capital Costs and Stock Prices
3M ago
Shionogi Wins Japan Nod for Pediatric Use of COVID-19 Drug XOCOVA
Premium
Company Announcements
Shionogi Wins Japan Nod for Pediatric Use of COVID-19 Drug XOCOVA
3M ago
Shionogi and F2G Post Positive Phase 3 Results for Novel Antifungal Olorofim
PremiumCompany Announcements
Shionogi and F2G Post Positive Phase 3 Results for Novel Antifungal Olorofim
3M ago
Ueda Boosts Shionogi to Buy, Raising 12‑Month Target to ¥3,400 on Stronger HIV Franchise and Xocova Upside
PremiumRatings
Ueda Boosts Shionogi to Buy, Raising 12‑Month Target to ¥3,400 on Stronger HIV Franchise and Xocova Upside
3M ago
Shionogi Wins Early FDA Nod for First Oral Post-Exposure COVID-19 Prophylactic
PremiumCompany Announcements
Shionogi Wins Early FDA Nod for First Oral Post-Exposure COVID-19 Prophylactic
4M ago
Shionogi Wins FDA Nod for First Oral COVID-19 Post-Exposure Preventive Drug
PremiumCompany Announcements
Shionogi Wins FDA Nod for First Oral COVID-19 Post-Exposure Preventive Drug
4M ago
Shionogi Wins China Approval for Naldemedine to Treat Opioid-Induced Constipation
PremiumCompany AnnouncementsShionogi Wins China Approval for Naldemedine to Treat Opioid-Induced Constipation
4M ago
Shionogi Outlines FY2025 Results, FY2026 Outlook and 2030 Strategy
Premium
Company Announcements
Shionogi Outlines FY2025 Results, FY2026 Outlook and 2030 Strategy
4M ago
Shionogi Lifts FY2025 Earnings and Projects Sharp Revenue Surge for FY2026
Premium
Company Announcements
Shionogi Lifts FY2025 Earnings and Projects Sharp Revenue Surge for FY2026
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >